BIOVIE INC. - *W EXP 08/08/203 (BIVIW)

CUSIP: 09074F173

Q3 2025 13F Holders as of 30 Sep 2025

Share change
+1,714,730
SEC-reported price per share
$0.44
Number of holders
9
Value change
+$775,100
Number of buys
9

Security key

09074F173

Report period

Q3 2025

Institutions

9

Top holders

9

Ownership snapshot

Top reported holders of BIVIW - BIOVIE INC. - *W EXP 08/08/203 (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Acuitas Group Holdings, LLC
Disclosed value leader
Acuitas Group Holdings, LLC
Comparable rows
1/15
Latest evidence
30 Jun 2025
13D/G 3/4/5 13F Lead comparable stake: 16% 14 rows are not safely comparable across share classes. 13D/G row: Acuitas Group Holdings, LLC Showing 1-6 of 15 holder rows.

Quick read

Acuitas Group Holdings, LLC leads the comparable SEC ownership view at 16%.

1 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Acuitas Group Holdings, LLC's linked filing trail.
Comparable ownership Top 1
Acuitas Group Holdings, LLC 16%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Acuitas Group Holdings, LLC
13D/G
TERREN S. PEIZER
16%
Reported 13D/G · 25 Jun 2025
$3,629,969
3,050,394 shares
$0 25 Jun 2025
Terren S. Peizer
3/4/5
Director, 10%+ Owner
—
denominator unverified
—
65,000 shares
— 23 Nov 2022
VANGUARD GROUP INC
13F
Company
13F
—
denominator unverified
$510,942
552,369 shares
— 30 Jun 2025
GEODE CAPITAL MANAGEMENT, LLC
13F
Company
13F
—
denominator unverified
$128,948
139,401 shares
— 30 Jun 2025
UBS Group AG
13F
Company
13F
—
denominator unverified
$113,028
122,192 shares
— 30 Jun 2025
Jonathan M. Adams
3/4/5
EVP Liver Cirrhosis Programs
—
denominator unverified
$82,185
48,630 shares
— 02 Feb 2022
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q3 2025

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
9
Shares
1,714,730
Rows available
9
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q3 2025 vs Q2 2026 Across Filers

Q2 2026 holders
8
Q3 2025 holders
9
Holder diff
1
Investor Q2 2026 Shares Q3 2025 Shares Share Diff Share Chg % Q2 2026 value Q3 2025 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .